ArticlePPAR research2008
PPAR Ligands for Cancer Chemoprevention.
Article in PPAR research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Potential Chemopreventive Effects of Dietary Combination of Phytochemicals against Cancer Development.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Review
- The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism.Molecules (Basel, Switzerland) · 2019Article
- StandardizedIranian journal of pharmaceutical research : IJPR · 2019Article
- Marine low molecular weight natural products as potential cancer preventive compounds.Marine drugs · 2014Review
- A comparison of peroxisome proliferator-activated receptor-α agonist and antagonist on human umbilical vein endothelial cells angiogenesis.Advanced biomedical research · 2013Article
- Preclinical cancer chemoprevention studies using animal model of inflammation-associated colorectal carcinogenesis.Cancers · 2012Article
- Cancer chemoprevention by carotenoids.Molecules (Basel, Switzerland) · 2012Review
- Altered peroxisome-proliferator activated receptors expression in human endometrial cancer.PPAR research · 2012Article
- Cancer chemopreventive ability of conjugated linolenic acids.International journal of molecular sciences · 2011Review
- The use of Cox-2 and PPARγ signaling in anti-cancer therapies.Experimental and therapeutic medicine · 2010Article
- Prognostic and therapeutic potential of nuclear receptors in head and neck squamous cell carcinomas.Journal of oncology · 2009Article
- Protein expression analysis of inflammation-related colon carcinogenesis.Journal of carcinogenesis · 2009Article
- PPARalpha Ligands as Antitumorigenic and Antiangiogenic Agents.PPAR research · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peroxisome proliferators-activated receptors (PPARs) that are members of the nuclear receptor superfamily have three different isoforms: PPARalpha, PPARdelta, and PPARgamma. PPARs are ligand-activated transcription factors, and they are implicated in tumor progression, differentiation, and apoptosis. Activation of PPAR isoforms lead to both anticarcinogenesis and anti-inflammatory effect. It has so far identified many PPAR ligands including chemical composition and natural occurring. PPAR ligands are reported to activate PPAR signaling and exert cancer prevention and treatment in vitro and/or in vivo studies. Although the effects depend on the isoforms and the types of ligands, biological modulatory activities of PPARs in carcinogenesis and disease progression are attracted for control or combat cancer development. This short review summarizes currently available data on the role of PPAR ligands in carcinogenesis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.